Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC11A2 | P49281 | 1/20 | 0.36 |
| ▸ | HEXA | P06865 | 1/20 | 0.35 |
| ▸ | HEXB | P07686 | 1/20 | 0.35 |
| ▸ | ARF6 | P62330 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 7/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275302 | 0.85 | KIF11 (0.40) | SLC11A2HEXAHEXBARF6PDE2A | |
| SCHEMBL10275393 | 0.80 | ARF6 (0.35) | ARF6PDE2APDE5APLAT | |
| SCHEMBL10275704 | 0.80 | PDE2A (0.43) | SLC11A2PDE2APDE5APLATRAB9A | |
| SCHEMBL10275550 | 0.79 | ARF6 (0.41) | ARF6 | |
| SCHEMBL10313459 | 0.77 | PDE2A (0.41) | SLC11A2PDE2APDE5APLATTNKS | |
| SCHEMBL27943291 | 0.76 | PLAT (0.43) | SLC11A2PDE2AKDM4EPLATTNKS | |
| SCHEMBL10275224 | 0.75 | ARF6 (0.41) | SLC11A2HEXAHEXBARF6PDE2A | |
| SCHEMBL10275766 | 0.74 | MAPT (0.43) | ARF6KDM4EALDH1A1PLAT | |
| SCHEMBL10275278 | 0.73 | KIF11 (0.43) | SLC11A2ARF6PDE2APDE5APLAT | |
| SCHEMBL10275770 | 0.71 | CNR1 (0.41) | SLC11A2PDE2APDE5APLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | SLC11A2 4127/4885HEXA 255/4885HEXB 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.